(RVMD) Revolution Medicines - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76155X1000

RAS Inhibitors, Companion Inhibitors

Biotechnology
Market Cap in USD: 20,761m
IPO / Inception: 2020-02-13
12m vs SPY: 133%

EPS (Earnings per Share)

EPS (Earnings per Share) of RVMD over the last years for every Quarter: "2020-12": -0.52, "2021-03": -0.53, "2021-06": -0.6, "2021-09": -0.72, "2021-12": -0.71, "2022-03": -0.78, "2022-06": -0.82, "2022-09": -0.87, "2022-12": -0.63, "2023-03": -0.72, "2023-06": -0.92, "2023-09": -0.99, "2023-12": -1.14, "2024-03": -0.7, "2024-06": -0.81, "2024-09": -0.94, "2024-12": -1.12, "2025-03": -1.13, "2025-06": -1.31, "2025-09": -1.61, "2025-12": 0,
EPS CAGR: 17.80%
EPS Trend: -10.0%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of RVMD over the last years for every Quarter: 2020-12: 8.751, 2021-03: 10.131, 2021-06: 8.698, 2021-09: 1.101, 2021-12: 9.46, 2022-03: 7.578, 2022-06: 9.116, 2022-09: 3.356, 2022-12: 15.33, 2023-03: 7.014, 2023-06: 3.824, 2023-09: 0, 2023-12: 0.742, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 261.592, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: -64.22%
Rev. Trend: -44.2%
Last SUE: -0.17
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 58.5%
Value at Risk 5%th 82.0%
Relative Tail Risk -14.75%
Reward TTM
Sharpe Ratio 2.11
Alpha 165.63
CAGR/Max DD 1.32
Character TTM
Hurst Exponent 0.411
Beta 1.033
Beta Downside 1.005
Drawdowns 3y
Max DD 48.63%
Mean DD 17.48%
Median DD 13.15%

Description: RVMD Revolution Medicines January 07, 2026

Revolution Medicines (NASDAQ: RVMD) is a clinical-stage precision-oncology firm that concentrates on “RAS-addicted” cancers. Its RAS(ON) inhibitor program targets mutant KRAS isoforms-including daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) and zoldonrasib G12D (RMC-9805)-all currently in Phase 1. The pipeline also includes next-generation candidates (RMC-5127 G12V, RMC-0708 Q61H, RMC-8839 G13C) and a suite of RAS companion agents such as RMC-4630 (Phase 2), the mTORC1-selective RMC-5552 (Phase 1), and the SOS1 inhibitor RMC-5845.

As of the most recent filing (Q4 2024), RVMD reported a market capitalization of roughly $1.1 billion and cash-and-equivalents of $210 million, giving the company an estimated 12-month runway at current burn rates. The global KRAS-targeted oncology market is projected to grow at a CAGR of 12-15 % through 2030, driven by the success of first-in-class KRAS G12C inhibitors (e.g., Amgen’s sotorasib) and the unmet need for G12D/G12V agents. Competitive pressure is high, but Revolution’s “RAS-ON” binding approach-aimed at maintaining KRAS in its active conformation-differs mechanistically from the “off-state” covalent inhibitors, potentially enabling synergistic combos and broader mutation coverage.

For a deeper quantitative view, the ValueRay platform offers a granular breakdown of RVMD’s valuation metrics and scenario analyses.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-961.0m TTM) > 0 and > 6% of Revenue (6% = 15.7m TTM)
FCFTA -0.35 (>2.0%) and ΔFCFTA -3.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 662.0% (prev 197.9k%; Δ -197.2kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.34 (>3.0%) and CFO -761.8m > Net Income -961.0m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (189.2m) change vs 12m ago 13.42% (target <= -2.0% for YES)
Gross Margin -52.01% (prev -56.4k%; Δ 56.3kpp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 13.03% (prev 0.04%; Δ 12.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -82.39 (EBITDA TTM -1.00b / Interest Expense TTM 12.3m) >= 6 (WARN >= 3)

Altman Z'' -5.99

(A) 0.77 = (Total Current Assets 1.98b - Total Current Liabilities 245.6m) / Total Assets 2.25b
(B) -1.11 = Retained Earnings (Balance) -2.50b / Total Assets 2.25b
warn (B) unusual magnitude: -1.11 — check mapping/units
(C) -0.51 = EBIT TTM -1.02b / Avg Total Assets 2.01b
(D) -3.82 = Book Value of Equity -2.50b / Total Liabilities 655.0m
Total Rating: -5.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.13

1. Piotroski 0.0pt
2. FCF Yield -4.09%
3. FCF Margin data missing
4. Debt/Equity 0.10
5. Debt/Ebitda 0.06
6. ROIC - WACC (= -50.80)%
7. RoE -49.25%
8. Rev. Trend -44.18%
9. EPS Trend -10.01%

What is the price of RVMD shares?

As of January 14, 2026, the stock is trading at USD 119.95 with a total of 3,882,243 shares traded.
Over the past week, the price has changed by +50.22%, over one month by +51.84%, over three months by +146.05% and over the past year by +181.77%.

Is RVMD a buy, sell or hold?

Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
  • Strong Buy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RVMD price?

Issuer Target Up/Down from current
Wallstreet Target Price 84.1 -29.9%
Analysts Target Price 84.1 -29.9%
ValueRay Target Price 158.5 32.1%

RVMD Fundamental Data Overview January 10, 2026

P/S = 9035.0954
P/B = 13.0005
Beta = 0.99
Revenue TTM = 261.6m USD
EBIT TTM = -1.02b USD
EBITDA TTM = -1.00b USD
Long Term Debt = 158.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.3m USD (from shortTermDebt, last quarter)
Debt = 158.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.99b USD (20.76b + Debt 158.5m - CCE 1.93b)
Interest Coverage Ratio = -82.39 (Ebit TTM -1.02b / Interest Expense TTM 12.3m)
EV/FCF = -24.43x (Enterprise Value 18.99b / FCF TTM -777.1m)
FCF Yield = -4.09% (FCF TTM -777.1m / Enterprise Value 18.99b)
FCF Margin = -297.1% (FCF TTM -777.1m / Revenue TTM 261.6m)
Net Margin = -367.4% (Net Income TTM -961.0m / Revenue TTM 261.6m)
Gross Margin = -52.01% ((Revenue TTM 261.6m - Cost of Revenue TTM 397.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 8.43 (Enterprise Value 18.99b / Total Assets 2.25b)
Interest Expense / Debt = 7.21% (Interest Expense 11.4m / Debt 158.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -802.3m (EBIT -1.02b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.05 (Total Current Assets 1.98b / Total Current Liabilities 245.6m)
Debt / Equity = 0.10 (Debt 158.5m / totalStockholderEquity, last quarter 1.60b)
Debt / EBITDA = 0.06 (negative EBITDA) (Net Debt -59.0m / EBITDA -1.00b)
Debt / FCF = 0.08 (negative FCF - burning cash) (Net Debt -59.0m / FCF TTM -777.1m)
Total Stockholder Equity = 1.95b (last 4 quarters mean from totalStockholderEquity)
RoA = -47.87% (Net Income -961.0m / Total Assets 2.25b)
RoE = -49.25% (Net Income TTM -961.0m / Total Stockholder Equity 1.95b)
RoCE = -48.13% (EBIT -1.02b / Capital Employed (Equity 1.95b + L.T.Debt 158.5m))
RoIC = -41.11% (negative operating profit) (NOPAT -802.3m / Invested Capital 1.95b)
WACC = 9.69% (E(20.76b)/V(20.92b) * Re(9.72%) + D(158.5m)/V(20.92b) * Rd(7.21%) * (1-Tc(0.21)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.77%
Fair Price DCF = unknown (Cash Flow -777.1m)
EPS Correlation: -10.01 | EPS CAGR: 17.80% | SUE: 4.0 | # QB: 1
Revenue Correlation: -44.18 | Revenue CAGR: -64.22% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.65 | Chg30d=+0.008 | Revisions Net=+0 | Analysts=8
EPS next Year (2026-12-31): EPS=-6.29 | Chg30d=-0.013 | Revisions Net=-6 | Growth EPS=-13.4% | Growth Revenue=+903.5%

Additional Sources for RVMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle